Prevest Denpro Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Revenue up 14%, but margins compressed: PAT margin fell ~300 bps to 27.22% as depreciation and other expenses from the new R&D centre and Oradox launch weighed on profitability.
• Domestic story is the engine: India sales grew 26.47%, now 42-44% of revenue, driven by the new Oradox oral care line; exports were flat as currency crises and recession hit key markets.
• FY25 growth bet is aggressive: Management targets a minimum 30% revenue growth, hinging on Oradox scaling, a disinfectant launch, and a hoped-for export recovery in challenged regions.
• The balance sheet is stretching: Debtor days nearly doubled to 53 as export customers in Africa and Europe shifted from advance payments to letters of credit, while domestic sales moved to farther geographies.
• What to watch next quarter: Whether the 30% growth target gains traction in Q1, the pace of Oradox's pharmacy channel rollout, and any sign that debtor days are stabilising.

The Oradox Bet & Domestic Expansion

• Specialty positioning, not mass-market: Oradox targets specialty mouthwashes, not the OTC segment occupied by Colgate and similar brands; management sees this as a differentiated, less crowded niche.
• Channel expansion underway: The brand is already on Tata 1MG, Flipkart, Amazon and Jiomart; the company is testing a pharmacy channel rollout in one state with plans to scale further.
• Product pipeline filling: More Oradox products are expected in the next three to four months, adding to the range launched in FY24.
• India distribution deepening: The company is hiring sales staff and adding distributors in states where market share is lower; some hires are already in place.
• Online contribution still small: E-commerce across all channels contributed approximately 8-10% of India revenue in FY24, per management's estimate.

Modi: "We are not competing with the already existing mouthwash and other oral hygiene care brands. You know, like Colgate who have mouthwashes just for the OTC, over-the-counter kind of things. They don't have specialty mouthwashes and that is the area we are aiming to be in."

Export: Flat Now, Recovery Bet Later

• Broad-based stagnation: Export results from major countries were flat in FY24; small growth came from Europe, South America and the US, while African and some South American countries were significant challenges.
• Currency and war as root causes: Management cited currency exchange crises and recessionary conditions in EU countries stemming from the prolonged Russia-Ukraine war as the primary drags.
• US inching forward: US export share grew from 2.87% to 3.6%; management noted products are new and acceptability takes time, but response has been good and private-label work is already underway.
• UK emerging: The UK was called out as a market that is "emerging as a big market" for the company's products, with tremendous response from dental professionals at exhibitions.
• FY25 export optimism is broad but unquantified: Management expects better growth from the US, Saudi Arabia, and even African countries where business has not been growing fast, but gave no country-level targets.

Modi: "The present export scenario is not very good because the result from major countries where we are exporting are flat."

Margin Pressure & Cost Build-Up

• Three margin hits at once: PAT margin fell from 30.28% to 27.22%, driven by higher depreciation from the new R&D setup and new production line, plus a 90% YoY rise in other expenses covering exhibitions, advertisements and facility expansion.
• EBITDA margin also down: EBITDA margin declined from 41.69% to 38.30%, attributed to marketing, exhibition costs, employee additions and ancillary activities tied to the Oradox launch.
• Headcount nearly doubled: Employee count rose 78% as the company hired across manufacturing, sales, marketing, administration and R&D, all in anticipation of higher growth that has not yet fully materialised.
• Export margin cushion exists: Margins are 10-12% higher on exports because products sell at higher international prices; a recovery in export volumes would therefore be margin-accretive.
• Management's margin thesis: With maximum capex now incurred, the company expects those investments to become beneficial and margins to improve, though costs will keep rising from more employees, conferences and educational programs.

New Facilities, Products & R&D

• DSIR-recognised research centre: Prevest became the first Indian dental company to set up a research centre approved by the Ministry of Science and Technology, a credential management highlighted as a competitive differentiator.
• Disinfectant line imminent: Trials are complete, regulatory compliance is in place, and commercial production is about to start, completing a new product line adjacent to the core dental portfolio.
• 3D resin gaining traction: Marketing has begun and response is positive both in India and outside; management expects "very good" performance in FY25, though no figures were provided for the current base.
• Academic pipeline building: Around 17 academic institutions are tied up; the company is exploring MoUs and joint technology development programs with IIT Jammu, with interns already coming from IIT Jammu and Central University Jammu.
• Capacity headroom: 55% of capacity remains unutilised, providing room to scale without immediate further capex.

Modi: "The products which we manufacture are very technical products. The formulations have been developed in-house with our own internal research and development efforts. So these are formulations which are not, common formulation, not easily available."

Working Capital & Cash Deployment

• Debtor days doubled: Debtor days rose from 31 to 53, driven by two forces: export customers in Africa and Europe shifting from advance payments to letters of credit and cash against documents amid cash crunches, and domestic sales extending to farther geographies, though still mostly on a COD basis.
• Inorganic growth on the radar: Management is actively exploring acquisitions, primarily outside India but open to domestic opportunities; due diligence is underway with multiple companies.
• Dividend continuity likely: The company will take a "positive look" at continuing its dividend policy, though no decision has been made yet.
• Grey market risk flagged: Unauthorised listings of company products on eBay UK and Amazon US have been identified; management has raised the issue with the USFDA since these are regulated products that cannot legally be sold on e-commerce platforms in the US.

Modi: "The sellers are not officially allowed to sell the product on these platforms. We have raised this concern with the USFDA because, you know, these products cannot be sold on the e-commerce platforms in the US because these are regulated products."

Guidance & Commitments

Key Metrics